Aggregation of lipoprotein(a) to apolipoprotein A-I underlying HDL dysfunction as a major coronary risk factor;HDL disfonksiyonunun temelindeki lipoprotein(a)'ni{dotless}n apolipoprotein A-I'e agregasyonu majör bir koroner risk faktörüdür

Anadolu Kardiyoloji Dergisi

Volumn 13, Issue 6, 2013, Pages 543-551

  Onat, Altan ^a   Can, Günay ^b   Murat, Sani ^c   Çiçek, Gökhan ^d   Örnek, Ender ^c   Yüksel, Hüsniye ^b  

^a Turkish Society of Cardiology   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Etlik Ihtisas Educational Hospital   (Turkey)

^d DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Apolipoprotein A I; Apolipoprotein E; Coronary heart disease; HDL dysfunction; Lipoprotein(a); Metabolic syndrome; Regression analysis

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; COMPLEMENT COMPONENT C3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; TRIACYLGLYCEROL; APOLIPOPROTEIN A-I; LIPOPROTEIN(A);

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISORDERS OF CHOLESTEROL METABOLISM; ETHNIC GROUP; FEMALE; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PROTEIN AGGREGATION; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; TURKISH; AGED; BLOOD; COMPLICATION; CORONARY ARTERY DISEASE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; TURKEY;

AGED; APOLIPOPROTEIN A-I; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; INCIDENCE; LIPOPROTEIN(A); MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; TURKEY;

EID: 84884748412     PISSN: None     EISSN: 13080032     Source Type: Journal    
DOI: 10.5152/akd.2013.175     Document Type: Article

References (37)

1. Onat A, Hergenc G, Bulur S, Uǧur M, Kucukdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2010; 142: 72-9. [CrossRef]
2. Onat A, Can G, Ayhan E, Kaya Z, Hergenc G. Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 2009; 58: 1393-9. [CrossRef]
3. Onat A, Hergenc G. Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 2011; 60: 499-512. [CrossRef]
4. Onat A, Komurcu-Bayrak E, Can G, Kucukdurmaz Z, Hergenc G, Erginel-Unaltuna N. Apolipoprotein A-I positively associated with diabetes in women independently of apo E genotype and apolipoprotein B levels. Nutrition 2010; 26: 975-80. [CrossRef]
5. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 2004; 37: 333-43. [CrossRef]
6. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality. JAMA 2009; 302: 412-23. [CrossRef]
7. Onat A, Hergenc G, Ozhan H, Kaya Z, Bulur S, Ayhan E, et al. Lipoprotein(a) is associated with coronary heart disease independent of metabolic syndrome. Coron Artery Dis 2008; 19: 125-31. [CrossRef]
8. Ogasawara K, Mashiba S, Hashimoto H, Kojima S, Matsuno S, Takeya M, et al. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease. Clin Chim Acta 2008; 397: 42-7. [CrossRef]
9. Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M, et al. Lipoprotein(a) levels and risk of future coronary heart disease.: large-scale prospective data. Arch Intern Med 2008; 168: 598-608. [CrossRef]
10. Werba JP, Safa O, Gianfranceschi G, Michelagnoli S, Sirtori CR, Franceschini G. Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population. Atherosclerosis 1993; 101: 203-11. [CrossRef]
11. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353: 46-57. [CrossRef]
12. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-53. [CrossRef]
13. Corsetti JP, Bakker SJ, Sparks CE, Dullaart RP. Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease in women with high levels of HDL cholesterol and C-reactive protein. PLoS One 2012; 7: e39110. [CrossRef]
14. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001; 156: 1-10. [CrossRef]
15. Grundy SM, Brewer HB, Cleeman JI, Smith SC Jr, Lenfant C. American Heart Association. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-8. [CrossRef]
16. Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007; 191: 182-90. [CrossRef]
17. Rose G, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods, 2nd Ed. 1982; Geneva, Switzerland: WHO: 124-7.
18. Bdeir K, Cane W, Canziani G, Chaiken I, Weisel J, Koschinsky ML, et al. Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood 1999; 94: 2007-19.
19. Greco TP, Conti-Kelly AM, Anthony JR, Greco T Jr, Doyle R, Boisen, et al. Oxidized-LDL/s2-glycoprotein I complexes are associated with disease severity and increased risk for adverse outcomes in patients with acute coronary syndromes. Am J Clin Pathol 2010; 133: 737-43. [CrossRef]
20. Lopez LR, Buckner TR, Hurley BL, Kobayashi K, Matsuura E. Determination of oxidized low-density lipoprotein (ox-LDL) versus ox-LDL/beta2-GPI complexes for the assessment of autoimmune-mediated atherosclerosis. Ann N Y Acad Sci 2007; 1109: 303-10. [CrossRef]
21. The Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000. [CrossRef]
22. Onat A, Hergenc G, Ayhan E, Kaya Z, Kucukdurmaz Z, Bulur S, et al. Serum apolipoprotein E concentrations among Turks: Additive information to genotype relative to dyslipidemia and metabolic syndrome. Turk Kardiyol Dern Arş 2007; 35: 449-57.
23. Onat A, Can G, Ornek E, Ayhan E, Erginel-Unaltuna N, Murat SN. High serum apolipoprotein E determine hypertriglyceridemic dyslipidemias, coronary disease and apo A-I dysfunctionality. Lipids 2013; 48: 51-61. [CrossRef]
24. Zechner R, Desoye G, Schweditsch MO, Pfeiffer KP, Kostner GM. Fluctuations of plasma lipoprotein(a) concentrations during pregnancy and postpartum. Metabolism 1986; 35: 333-6. [CrossRef]
25. Bersot TP, Innerarity RW, Pitas RE, Rall SC Jr, Weisgraber KH, Mahley RW. Fat feeding in humans induces lipoproteins of density less than 1. 006 that are enriched in apolipoprotein(a) and that cause lipid accumulation in macrophages. J Clin Invest 1986; 77: 622-30. [CrossRef]
26. Rosseneu M, Labeur C, Vinaimont R, de Slypere JP, Matthys E. Plasma Lp(a) patterns after triglyceride infusion. Atherosclerosis 1991; 22: 137.
27. Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362: 906-16. [CrossRef]
28. Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58, 000 participants. J Am Coll Cardiol 2010; 55: 2160-7. [CrossRef]
29. Imaizumi S, Navab M, Morgantini C, Charles-Schoeman C, Su F, Gao F, et al. Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins. Circ J 2011; 75: 1533-8. [CrossRef]
30. Van den Elzen P, Garg S, Leon L, Brigl M, Leadbetter EA, Gumperz JE, et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 2005; 437: 906-10. [CrossRef]
31. Onat A, Hergenc G, Can G, Kaya Z, Yuksel H. Serum complement C3: a determinant of cardiometabolic risk, additive to metabolic syndrome, in middle-aged population. Metabolism 2010; 59: 628-34. [CrossRef]
32. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009; 32: 1924-9. [CrossRef]
33. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010; 375: 735-42. [CrossRef]
34. Taylor AJ, Villines TC, Stanek EJ. Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetemibe. Eur Heart J 2012; 33: 2939-45. [CrossRef]
35. Onat A, Can G, Ademoǧlu E, Celik E, Karagoz A, Ornek E. Coronary disease risk curve of serum creatinine is linear in Turkish men, U-shaped in women. J Investig Med 2013; 61: 27-33.
36. Tohidi M, Hatami M, Hadaegh F, Safarkhani M, Harati H, Azizi F. Lipid measures for prediction of incident cardiovascular disease in diabetic and non-diabetic adults: results of the 8. 6-year follow-up of a population based cohort study. Lipids Health Dis 2010; 9: 6. [CrossRef]
37. Zhang L, Qiao Q, Laatikainen T, Soderberg S, Jousilahti P, Onat A, et al, for the DECODE Study Group. The impact of dyslipidaemia on incidence of coronary heart disease in Finns and Swedes with different categories of glucose tolerance. Diabetes Res Clin Pract 2011; 91: 406-12. [CrossRef]